

|                          |                                   |                         |  |
|--------------------------|-----------------------------------|-------------------------|--|
| <b>Interview Summary</b> | <b>Application No.</b>            | <b>Applicant(s)</b>     |  |
|                          | 10/630,655                        | CRIPPS ET AL.           |  |
|                          | <b>Examiner</b><br>Mina Haghigian | <b>Art Unit</b><br>1616 |  |

All participants (applicant, applicant's representative, PTO personnel):

(1) Mina Haghigian.

(3) Richard Fichter.

(2) Johann Richter.

(4) \_\_\_\_\_.

Date of Interview: 01 August 2006.

Type: a) Telephonic b) Video Conference  
c) Personal [copy given to: 1) applicant 2) applicant's representative]

Exhibit shown or demonstration conducted: d) Yes e) No.  
If Yes, brief description: \_\_\_\_\_.

Claim(s) discussed: All.

Identification of prior art discussed: All.

Agreement with respect to the claims f) was reached. g) was not reached. h) N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Below.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER OF ONE MONTH OR THIRTY DAYS FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Mr. Fichter discussed that references do not teach a metered dose inhaler comprising a solution of fluticasone propionate without use of water (non-aqueous). Also Mr. Fichter argued that the 0.25 mm or less orifice has been shown to be advantageous in dispersion. It was agreed that claims are allowable at this time.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.



Examiner's signature, if required